Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) will present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on Tuesday, February 24, 2026 at 8:00 a.m. ET.
Management and Dr. Martin Steinberg will discuss the data via live webcast; registration is available on the company’s Events and Presentations page and a replay will be posted after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FULC gained 0.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FULC fell 2.12% while close biotech peers were mixed: AUTL up 0.72%, SLDB up 1.81%, LRMR down 2.17%, PRTC down 1.02%. Momentum scanner only flagged CGEM up 6.56%, suggesting stock-specific trading rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 06 | Inducement option grant | Neutral | +5.0% | Single-employee inducement stock option grant under 2022 plan. |
| Jan 09 | Inducement grants | Neutral | -3.5% | Inducement stock options to three new employees under listing rule. |
| Jan 07 | Conference participation | Neutral | -0.1% | Planned presentation at 44th Annual J.P. Morgan Healthcare Conference. |
| Dec 10 | Offering priced | Negative | -5.5% | Pricing of upsized public offering of stock and pre-funded warrants. |
| Dec 08 | Offering proposed | Negative | +46.0% | Proposed $150M common stock offering under effective registration. |
News has generally aligned with price moves; one recent dilutive offering headline coincided with a sharply positive reaction.
Over the last few months, Fulcrum’s news flow has centered on equity offerings, inducement grants, and corporate events. In Dec 2025, the company announced and then priced an upsized public offering totaling about $175.0 million, with the pricing day seeing a -5.48% move but the earlier proposed offering headline coinciding with a +45.96% reaction. More routine items like inducement grants and conference participation in Jan–Feb 2026 produced modest, mixed price responses. Today’s sickle cell data call fits into this pattern of event-driven trading around clinical and financing milestones.
Market Pulse Summary
This announcement highlights an upcoming clinical catalyst: 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease, to be discussed on February 24, 2026 at 8:00 a.m. ET. Recent history shows meaningful price moves around financing and event headlines, so investors may watch this call for signals on efficacy, safety, and how the program could progress in later-stage trials.
Key Terms
phase 1b medical
sickle cell disease medical
dose cohort medical
webcast technical
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease.
Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine.
To register for this event, please click here or visit the “Events and Presentations” section of Fulcrum’s website. A replay will be available on Fulcrum’s website following the event.
About Martin H Steinberg, MD
Dr. Martin H Steinberg, MD is a hematologist with a clinical and research focus on disorders of the red blood cell with special emphasis on sickle cell disease. He has published more than 450 articles and 3 textbooks on the science and clinical features of sickle cell disease and related disorders. A graduate of Cornell University and Tufts University School of Medicine he completed post-graduate training in New York and Boston. He has participated in basic, translational, and clinical studies devoted to understanding the pathophysiology and genetic basis of phenotypic heterogeneity in sickle cell disease. Using candidate gene, genome-wide association studies, next-generation sequencing, and induced pluripotent stem cells to understand the genetic determinants of sickle cell disease heterogeneity, Dr. Steinberg and his coworkers modeled disease severity and selected subphenotypes of disease to discover hitherto unsuspected genetic associations. He has also helped develop a widely accepted paradigm reimagining the pathophysiology of sickle cell disease as a combination of both sickle vasoocclusion and intravascular hemolysis. His most recent work focusses on the distribution of HbF concentrations among red cells of patients before and following HbF induction therapeutics.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
About Pociredir
Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the treatment of SCD. In the PIONEER Phase 1b clinical trial in people with SCD, pociredir has demonstrated dose-dependent increases in HbF, pan-cellular HbF induction, and improvements in markers of hemolysis and anemia. Across the 12 mg and 20 mg dose cohorts, pociredir has been generally well-tolerated with up to three months of exposure, with no treatment-related serious adverse events reported. Pociredir has been granted Fast Track and Orphan Drug Designation from the FDA for the treatment of SCD. To learn more about clinical trials of pociredir please visit ClinicalTrials.gov.
About Sickle Cell Disease
SCD is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and reduced life expectancy.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Fulcrum Therapeutics (FULC) present 12-week PIONEER 20 mg data?
How can investors register for the FULC February 24, 2026 webcast?
Who will present the PIONEER 12-week 20 mg cohort results for FULC?
What trial and dose will Fulcrum discuss on the February 24, 2026 call?
Will a replay of the FULC PIONEER presentation be available after the webcast?
What is the primary focus of the February 24, 2026 Fulcrum webcast for investors?
